NCT00437840View on ClinicalTrials.gov

A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 20, 2007

Primary Completion Date

June 20, 2007

Study Completion Date

June 20, 2007

Conditions
Substance Dependence
Interventions
DRUG

GSK598809

GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.

DRUG

Placebo

Subjects will receive single oral dose of matching placebo tablet to GSK598809.

Trial Locations (1)

13251

GSK Investigational Site, Berlin

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY